Skip to main content

Resmed Inc

RSMDF
Exchange
OTC
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000943819

In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 4 sales; 1 institution reported holding it in 13F filings for Q2 2026, worth $1.17K in total; no superinvestor holds it.

Other share classesRMD

Key figures

Market capClose on Nov 11, 2026
$33.6B
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $2.57M in total
4
13F holdersQ2 2026, 0 vs. previous quarter
1
13F valueReported value at the end of Q2 2026
$1.17K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2026
$5.65B
+9.9% year over year
Net income, FY2026
$1.52B
+8.8% year over year
Free cash flow, FY2026
$1.65B
−0.7% year over year
Revenue, Q1 FY2027
$1.41B
+5.9% year over year

Revenue flow, FY2026

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
287
Shares sold short
Change
−96.6K
−99.7% vs. previous
Days to cover
11.96
At average daily volume

Superinvestors holding RSMDF, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding RSMDF at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Resmed Inc insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 26, 2026 (view filing)3:39 PM ETOct 233 daysRider Michael JGlobal General CounselSSaleResMed Common Stock−400$255.00−$102.0K−3.1%12.3K after10b5-1
Oct 8, 2026 (view filing)5:31 PM ETOct 71 dayFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$226.33−$1.13M−1.0%479.8K after10b5-1
Sep 10, 2026 (view filing)6:40 AM ETSep 82 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$222.44−$1.11M−1.1%466.3K afterFrom original
Sep 4, 2026 (view filing)6:30 AM ETSep 22 daysFarrell Peter CDirectorSSaleResMed Common Stock−970$234.73−$227.7K−1.8%51.8K after10b5-1
Aug 11, 2026 (view filing)6:30 AM ETAug 74 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$205.69−$1.03M−1.1%466.3K after10b5-1
Aug 6, 2026 (view filing)2:29 PM ETAug 51 dayFarrell Peter CDirectorSSaleResMed Common Stock−8.00K$225.00−$1.80M−13.2%52.8K after10b5-1
Jul 9, 2026 (view filing)7:40 AM ETJul 72 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$218.55−$1.09M−1.1%466.2K after10b5-1
Jun 9, 2026 (view filing)Jun 81 dayFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$193.96−$968.1K−1.1%466.3K after10b5-1
May 11, 2026 (view filing)May 74 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$207.82−$1.04M−1.1%466.2K after10b5-1
Apr 9, 2026 (view filing)Apr 72 daysFarrell Michael J.Chairman and CEOSSaleResMed Common Stock−4.99K$225.50−$1.13M−1.1%466.2K after10b5-1

Top 10 13F holders, Q2 2026

See all 1 holders

The largest institutional positions in Resmed Inc at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding RSMDF in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
GAMMA Investing LLC70$1.17K0.00%−2,722−97.5%Reduced

6 members of Congress reported 17 trades in Resmed Inc since 2020. Newest filings:

  1. Tommy Tuberville

    Senate · AL · Aug 5, 2026

    Sell (full)$1K-$15K

  2. Alan Armstrong

    Senate · OK · Jul 21, 2026

    Buy$1K-$15K

  3. Kelly Morrison

    House · MN · Jun 18, 2025

    Sell$1K-$15K

  4. Kelly Morrison

    House · MN · Jun 18, 2025

    Sell$1K-$15K

  5. Kelly Morrison

    House · MN · Jun 18, 2025

    Sell$1K-$15K